Amendments to the Claims

1. (currently amended) An isolated nucleic acid molecule which encodes a peptide that can inhibit cell division, wherein ~~characterised in that~~ the nucleic acid molecule is ~~selected from the following group~~:

i) a nucleic acid molecule comprising the nucleic acid sequence presented in ~~figure 6~~ SEQ ID NO: 1;

ii) a nucleic acid molecule as represented by the sequence presented in ~~figure 6~~ SEQ ID NO: 1 which has been modified by addition, deletion or substitution of at least one nucleotide base within at least one codon to encode a variant peptide which has cell-cycle inhibitory activity;

iii) a nucleic acid molecule which hybridizes to the sequence in (i) or (ii); ~~and~~or

iv) a nucleic acid molecule comprising a nucleic acid sequence which is degenerate as a result of the genetic code to the sequences identified in (i)-(iii)~~; for the manufacture of a medicament for use in the treatment of diseases or conditions which would benefit from an inhibition of cell division~~.

2. (currently amended) A peptide encoded by the nucleic acid according to Claim 1, wherein the peptide can inhibit ~~for the manufacture of a medicament for use in the treatment of diseases or conditions which would benefit from the inhibition of~~ cell division or angiogenesis.

3. (canceled)

4. (currently amended) ~~A~~ The peptide according to ~~Claim 2 or 3~~ claim 2, wherein the peptide can treat ~~said disease is selected from the group consisting of:~~ cancer; psoriasis; neovascular glaucoma; rheumatoid arthritis; or diabetic retinopathy.

5. – 6. (canceled)

7. (currently amended) ~~A~~ The peptide according to ~~Claim 6~~ claim 4, wherein said psoriatic condition is ~~selected from the group consisting of:~~ nail psoriasis; scalp psoriasis; plaque psoriasis; pustular psoriasis; guttate psoriasis; inverse psoriasis; erythrodermic psoriasis; or psoriatic arthritis.

8. (currently amended) ~~A~~ The peptide ~~according to any of Claims 2-7~~ of claim 2, wherein said peptide comprises ~~an~~ the amino acid sequence~~, or part thereof, consisting of the amino acid sequence~~ ARYYSALRHYINLITRQRT (SEQ ID NO: 2).

9. (currently amended) ~~A~~ The peptide according to Claim 8, wherein said peptide is a peptide consisting of the amino acid sequence ARYYSALRHYINLITRQRT (SEQ ID NO: 2).

10. (currently amended) ~~A~~ The peptide ~~according to any of Claims 2-9~~ of claim 2, wherein said peptide is a fragment of ~~the peptide~~ ARYYSALRHYINLITRQRT (SEQ ID NO: 2).

11. (currently amended) ~~A~~ The peptide ~~according to any of Claims 2-10~~ of claim 2, wherein said peptide is acetylated.

12. (currently amended) ~~A~~ The peptide according to Claim 11, wherein said acetylation is to ~~the~~ an amino terminus of said peptide.

13. (currently amended) ~~A~~ The peptide ~~according to any of Claims 2-12~~ of claim 2, wherein said peptide is amidated.

14. (currently amended) ~~A~~ The peptide according to Claim 13, wherein said amidation is to ~~the~~ a carboxyl-terminus of said peptide.

15. (currently amended) ~~A~~ The peptide ~~according to any of Claims 2-10~~ of claim 2, wherein said peptide~~, or fragment thereof,~~ is modified by both acetylation and amidation.

16. (currently amended) ~~A~~ The peptide ~~according to any of Claims 2-15~~ of claim 2, wherein said peptide is modified by cyclisation.

17. (currently amended) An agent comprising two or more peptides of claim 2, ~~according to any of Claims 2-16~~ wherein said agent has cell-cycle inhibitory activity.

18. (currently amended) ~~An~~ The agent ~~according to Claim 17~~ of claim 17, wherein said two or more peptides are linked by a linker molecule.

19. (currently amended) ~~An~~ The agent ~~according to Claim 17 or 18~~ of claim 17, wherein said agent comprises a plurality of peptides.

20. (currently amended) ~~An~~ The agent ~~according to Claim 19~~ of claim 19, wherein said agent comprises 3, 4, 5, 6, 7, 8, 9, or 10 peptides linked together as an oligomeric peptide.

21. (currently amended) ~~An~~ The agent ~~according to Claim 17 or 18~~ of claim 17, wherein said peptide has greater than 10 peptides.

22. (currently amended) ~~An~~ The agent ~~according to Claim 17 or 18~~ of claim 17, wherein said agent is a dimer of two peptides.

23. (currently amended) ~~An~~ The agent ~~according to any of Claims 17-22~~ of claim 18, wherein said linker is a peptide linking molecule.

24. (currently amended) ~~An~~ The agent ~~according to Claim 23~~ of claim 23, wherein said peptide linking molecule comprises at least one amino acid residue which links at least two peptides.

25. (currently amended) ~~An~~ The agent ~~according to Claim 23 or 24~~ of claim 24, wherein said peptide linking molecule comprises at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues.

26. (currently amended) ~~An~~ The agent ~~according to Claim 23~~ of claim 23, wherein said linking molecule comprises more than 10 amino acid residues.

27. (currently amended) ~~An~~ The agent ~~according to any of Claims 17-26~~ of claim 17, wherein said agent is a fusion protein comprising an inframe translational fusion.

28. (canceled)

29. (currently amended) A pharmaceutical composition comprising the ~~an~~ agent of claim 17 ~~according to any of Claims 17-27~~.

30. (currently amended) A vector comprising ~~a~~ the nucleic acid molecule of claim 1~~which encodes a peptide and/or agent according to any of Claims 2-27~~.

31. (currently amended) A cell transformed/transfected with ~~a~~ the nucleic acid molecule of claim 1 ~~according to Claim 1 or a vector according to Claim 30~~.

32. (currently amended) A non-human, transgenic animal ~~characterised in that said animal incorporates a~~ comprising the nucleic acid molecule of claim 1 ~~encoding a peptide and/or agent according to any of Claims 2-27~~.

33. (currently amended) A combined preparation comprising ~~a~~ the peptide~~/agent according to any of Claims 2-27~~ of claim 2 and at least one cytotoxic agent.

34. (currently amended) A combined preparation comprising ~~a~~ the peptide~~/agent according to any of Claims 2-27~~ of claim 2 and at least one anti-angiogenic agent.

35. (currently amended) A method to treat an animal which would benefit from inhibition of cell-division comprising:

~~i)~~ administering an effective amount of the peptide of claim 2 ~~an agent comprising a peptide/agent according to any of Claims 2-27,~~ to ~~an~~ the animal ~~to be treated~~;

~~ii).~~ monitoring ~~the~~ effects of said ~~agent~~ peptide on the inhibition of cell-division.

36. (currently amended) ~~A~~ The method ~~according to Claim~~ of claim 35 wherein said treatment is ~~the~~ inhibition of tumour development.

37. (currently amended) A method of treating an animal which would benefit from inhibition of cell-division, comprising administering an effective amount of the ~~according to Claim 35 or 36~~ of claim 35, ~~wherein said agent is a~~ nucleic acid molecule of claim 1 to the animal ~~according to Claim 1 or a vector according to Claim 30~~.

38. (currently amended) An imaging agent comprising ~~a~~ the peptide of claim 2~~/agent according to any of Claims 2-27~~.

39. (currently amended) A peptide comprising the amino acid sequence ARYYSALRHYINLITRQRT (SEQ ID NO: 2), or a variant peptide wherein said sequence is modified by addition, deletion of substitution of at least one amino acid residue~~, for use as a pharmaceutical agent~~.

40. (currently amended) A pharmaceutical composition comprising the peptide of claim 39 ~~a peptide according to Claim 39~~.